Get the Stockscreener App
24.84
1.00%
-0.155
Oculis Holding Ag stock is traded at $24.84, with a volume of 2,107.
It is down -1.00% in the last 24 hours and down -17.47% over the past month.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
See More
Previous Close:
$25.00
Open:
$24.81
24h Volume:
2,107
Relative Volume:
0.01
Market Cap:
$1.45B
Revenue:
-
Net Income/Loss:
$-118.12M
P/E Ratio:
-10.90
EPS:
-2.2802
Net Cash Flow:
$-82.63M
1W Performance:
-2.44%
1M Performance:
-17.47%
6M Performance:
+40.39%
1Y Performance:
+25.89%
1-Day Range:
$24.81
$25.00
1-Week Range:
$24.02
$26.01
52-Week Range:
$14.00
$30.68
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
25.00 | 1.45B | 0 | -118.12M | -82.63M | -2.2802 |
VRTX
Vertex Pharmaceuticals Inc
|
452.54 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
752.21 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.05 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
691.35 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
146.63 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | JP Morgan | Overweight |
| Aug-27-25 | Initiated | Needham | Buy |
| Dec-05-23 | Initiated | Chardan Capital Markets | Buy |
| Oct-05-23 | Initiated | Stifel | Buy |
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
View All
Oculis Holding Ag Stock (OCS) Latest News
Understanding Momentum Shifts in (OCS) - Stock Traders Daily
Analyst Upgrade: How does Oculis Holding AG compare to its peers2026 Trading Recap & Weekly Stock Performance Updates - baoquankhu1.vn
Loss Report: Is Oculis Holding AG Equity Warrant a top pick in the sectorTrade Risk Summary & Technical Pattern Recognition Alerts - baoquankhu1.vn
Growth Recap: Is Oculis Holding AG Equity Warrant stock a value trap2026 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn
Aug Decliners: Will Oculis Holding AG benefit from green energy policiesWeekly Gains Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Sentiment Review: Is Oculis Holding AG Equity Warrant benefiting from interest rate changes2026 Winners & Losers & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Revenue Check: Can Oculis Holding AG Equity Warrant stock double in the next year2026 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn
Treasury Yields: Should I invest in Oculis Holding AG before earningsMarket Trend Summary & Community Trade Idea Sharing Platform - baoquankhu1.vn
Stop Loss: Whats the MACD signal for Oculis Holding AG2026 Stock Rankings & Momentum Based Trading Ideas - baoquankhu1.vn
Oculis Holding AG Presents Promising Phase 2 ACUITY Trial Results for Privosegtor at NANOS 2026 Meeting - Quiver Quantitative
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting - The Manila Times
Experimental eye drug aims to protect vision in optic neuritis - Stock Titan
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewswire
Oculis board member buys company stock on March 12 and 13 - Stock Titan
Oculis Holding AG (OCS) reports Q4 loss, tops revenue estimates - MSN
Short Interest in Oculis Holding AG (NASDAQ:OCS) Expands By 63.9% - MarketBeat
Latest OCS NewsOculis to Participate in Jefferies Healthcar... - Stock Titan
Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates - MSN
Risk Off: Can Oculis Holding AG beat the S P 500Portfolio Risk Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (OCS) Movement - Stock Traders Daily
Aug Opening: What is the implied volatility of Oculis Holding AG Equity WarrantWeekly Investment Report & Safe Capital Investment Plans - baoquankhu1.vn
H.C. Wainwright raises Oculis stock price target to $44 on trial progress - Investing.com Nigeria
Biopharma companies hire new legal executives - BioXconomy
Oculis (NASDAQ:OCS) Sees Large Volume IncreaseHere's What Happened - MarketBeat
OCS: Late-stage pipeline targets DME, dry eye, and neuroprotection, with major data readouts in 2024 - TradingView
[144] Oculis Holding AG SEC Filing - Stock Titan
Oculis (OCS) – Research Analysts’ Recent Ratings Updates - Defense World
Oculis Holding (NasdaqGM:OCS) Valuation Check After Strong Three Year Gains And Recent Share Price Pullback - Yahoo Finance
Oculis (NASDAQ:OCS) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Lifesci Capital Has Negative Estimate for Oculis Q1 Earnings - Defense World
Lifesci Capital Estimates Oculis' Q1 Earnings (NASDAQ:OCS) - MarketBeat
HC Wainwright Weighs in on Oculis' Q1 Earnings (NASDAQ:OCS) - MarketBeat
Why Oculis (OCS) Is Down 6.2% After New Equity Programs To Fund Late-Stage Trials - Sahm
Oculis (NASDAQ:OCS) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
H.C. Wainwright raises Oculis stock price target to $44 on trial progress By Investing.com - Investing.com South Africa
Oculis Holding AG Announces Participation in Upcoming Investor Conferences and Highlights Late-Stage Pipeline Developments - Quiver Quantitative
Oculis to Participate in Upcoming Investor Conferences - Yahoo Finance
Oculis Holding AG renews $100 million at-the-market offering program - Investing.com Australia
Stifel raises Oculis stock price target to $50 on pipeline progress - Investing.com Nigeria
Oculis Holding AG renews $100 million at-the-market offering program By Investing.com - Investing.com South Africa
Oculis Files 2025 Financials and Renews $100 Million ATM Program - TipRanks
Oculis Holding (NASDAQ: OCS) widens loss but ends 2025 with strong cash and $100m ATM capacity - Stock Titan
Oculis price target raised to $44 from $42 at H.C. Wainwright - TipRanks
RSU awards vest for Oculis board director Arshad Khanani - Stock Titan
Oculis (NASDAQ: OCS) 2025 20-F details losses, cash and trials - Stock Titan
HC Wainwright Issues Positive Forecast for Oculis (NASDAQ:OCS) Stock Price - MarketBeat
Oculis (NASDAQ:OCS) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):